Impact of sex on multiple sclerosis therapy.

Neurotherapeutics · 2025 · PMC12418430 · PMID 40545384

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a phase 2 trial of combination glatiramer acetate 20 mg SC daily, with either daily oral estriol 8 mg or placebo, the primary outcome (ARR at 2 years) showed a trend but was not significant [ 71 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.